Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Delisting risk
confidence 98%
filed 2026-08-25
Item 3.01
BEST SPAC I received a deficiency notification from Nasdaq on August 19, 2026, stating that the Company no longer meets the minimum Market Value of Listed Securities (MVLS) of $35,000,000 required under Nasdaq Listing Rule 5550(b)(2), and also fails to meet alternative requirements under Rules 5550(b)(1) and 5550(b)(3). The Company has been granted a 180-day compliance period until February 15, 2027, with explicit warning that failure to regain compliance will result in written delisting notification. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-25
EX-99.1
TNL Mediagene received a Nasdaq Hearings Panel decision on August 23, 2026, granting continued listing subject to strict conditions: compliance with the minimum bid price requirement by September 21, 2026, and the stockholders' equity requirement by October 30, 2026. The press release explicitly states "There can be no assurance that the Company will satisfy the conditions of the Panel's decision or otherwise regain compliance with the applicable listing requirements, and a failure to do so would result in the delisting of the Company's securities from Nasdaq." This is a material delisting-risk disclosure under Item 3.01 equivalent, as the company faces imminent delisting if it fails to meet two quantifiable compliance milestones within 66 days.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-25
Item 8.01
OSR Health disclosed a Staff Determination Letter from Nasdaq notifying the company of its determination to delist the company's common stock and warrants for non-compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company submitted a timely hearing request on August 25, 2026, which will stay formal delisting pending the Panel's decision, but trading suspension is scheduled for August 26, 2026. This is a clear delisting risk disclosure under Item 8.01, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-25
The 6-K discloses that Masonglory has regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)) after receiving a non-compliance notice on March 13, 2026. While the current filing announces resolution of the delisting risk through a share consolidation that restored the stock price above $1.00, the underlying event—the company's prior failure to maintain minimum listing standards and the associated delisting threat—is material to investors' assessment of the registrant's listing status and financial condition.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 96%
filed 2026-08-25
Item 3.01
Maison Solutions received a notification letter from Nasdaq on August 20, 2026, stating that the Company failed to timely file its Form 10-K for fiscal year ended April 30, 2026, and therefore no longer satisfies Nasdaq Listing Rule 5250(c)(1). The Company has 60 days to submit a compliance plan or face potential delisting.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-25
Item 3.01
BioRestorative Therapies received a delinquency notification from Nasdaq on August 21, 2026, for failure to timely file its Form 10-Q, placing the company in non-compliance with Nasdaq Listing Rule 5250(c)(1). The company has until October 20, 2026, to submit a compliance plan and until February 16, 2027, to regain compliance, with explicit risk of delisting if it fails to do so. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-25
EX-99.1
The exhibit discloses that TechCreate's Class A ordinary shares are subject to delisting proceedings initiated by NYSE American Staff, with a Panel decision dated August 20, 2026 affirming the determination to commence delisting. The Company intends to request review by the NYSE Committee for Review by September 4, 2026. Trading in the shares remains suspended following an SEC trading suspension effective February 2, 2026 based on potential share manipulation. This is a material delisting risk that directly threatens the Company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-25
The filing discloses Item 3.01 notification from Nasdaq that Aimei Health Technology's Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS) have fallen below minimum thresholds ($50 million and $15 million respectively) for 30 consecutive business days. The company has 180 days to regain compliance or face delisting, with the option to transfer to The Nasdaq Capital Market. This is a clear delisting risk disclosure materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-08-25
The filing discloses multiple delisting risks under Item 8.01. Nasdaq notified the Company on August 25, 2026 that it must evidence compliance with the $2.5 million stockholders' equity requirement in its next periodic report or face delisting, and separately granted an additional 180-day extension (until February 22, 2027) to regain compliance with the Minimum Price Listing Requirement after the stock closed below $1.00 for 30 consecutive business days. Additionally, the Cy Biopharma acquisition triggers a Change of Control requiring the post-transaction company to satisfy Nasdaq's initial listing criteria, with failure to do so resulting in trading suspension. These are material threats to the Company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-25
Item 3.01
Quartzsea received a delisting notice from Nasdaq on August 19, 2026 for failure to pay required listing fees under Nasdaq Rule 5250(f). Although the Company paid the $75,000 outstanding balance on August 25, 2026, Nasdaq had not yet confirmed withdrawal of the delisting determination as of the 8-K filing date, leaving material uncertainty about continued listing status. The disclosure explicitly states trading suspension was scheduled for August 28, 2026 absent a successful appeal or cure confirmation.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-08-24
Item 8.01
The filing discloses that Beasley Broadcast Group has regained compliance with Nasdaq's Minimum Stockholders' Equity Requirement after previously falling below the $2.5 million threshold in April 2026. While this represents resolution of a delisting risk rather than an active threat, the disclosure of the prior non-compliance and subsequent remediation is material to investors assessing the company's financial stability and listing status. The event directly addresses continued listing qualification under Nasdaq Rule 5550(b)(1).
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-08-24
Item 3.01
Hub Group received a deficiency notice from Nasdaq on August 20, 2026, for failure to timely file its Form 10-Q for Q2 2026, placing it in non-compliance with Nasdaq Listing Rule 5250(c)(1). The Company has until August 27, 2026 to submit a compliance plan and faces a maximum 180-day cure period ending September 14, 2026, with potential delisting if compliance cannot be regained.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-24
Item 8.01
Tenon Medical disclosed that it has regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)) following a reverse stock split. The company had previously received a non-compliance notice on February 25, 2026, and has now resolved this delisting risk through the 1-for-35 reverse split effective August 10, 2026. This is a material event because the minimum bid price requirement is a continued listing standard, and failure to maintain compliance directly threatens the company's continued listing on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-08-24
Item 5.03
Longeveron implemented a 1-for-10 reverse stock split, approved by stockholders on July 1, 2026 and effective August 26, 2026, to regain compliance with Nasdaq Capital Market's $1.00 minimum bid price requirement for continued listing. The amendment to the Certificate of Incorporation was filed August 20, 2026, reducing outstanding shares from approximately 30.4 million to 3.0 million.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-24
Item 3.01
Senmiao Technology received a Nasdaq notification on August 21, 2026, that it failed to maintain the minimum $2,500,000 stockholders' equity required under Listing Rule 5550(b)(1), with reported stockholders' equity of negative $35,344,336 as of June 30, 2026. The company has 45 days to submit a compliance plan or face potential delisting. This is a direct notice of failure to satisfy a continued listing standard, the core definition of delisting_risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-24
Item 3.01
Nasdaq notified the Company on August 21, 2026, that its market value of listed securities (MVLS) fell below the $50 million minimum requirement under Nasdaq Listing Rule 5450(b)(2)(A). The Company has 180 calendar days until February 17, 2027, to regain compliance; failure to do so will trigger delisting proceedings. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued exchange listing.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-24
Item 3.01
La Rosa received a notice from Nasdaq on August 21, 2026, that it failed to comply with Nasdaq Listing Rule 5250(c)(1) due to delinquent filing of its Form 10-Q. Although the company subsequently filed the Form 10-Q on August 21 and regained compliance by August 24, the notice documented the initial non-compliance and potential delisting risk, with Nasdaq retaining discretion to grant up to 180 days to regain compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-08-24
The filing discloses that Ensysce is at risk of delisting from Nasdaq due to failure to meet the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(1). While the company states it has requested a second 180-day grace period and believes it satisfies the minimum stockholders' equity requirement, the core disclosure centers on the company's delisting risk and its efforts to maintain continued listing compliance. This is material to investors as it directly threatens the registrant's continued trading on a major exchange.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-24
Item 3.01
NYSE Regulation has issued a formal Notice of unsuitability for continued listing under Sections 1001, 1002(e), 1003, and 1007 of the NYSE American Company Guide and has commenced delisting proceedings. The Company's Common Stock has been suspended from trading effective immediately and is expected to transfer to OTC Markets quotation. This is a textbook delisting event under Item 3.01, materially affecting liquidity, investor base, and the Company's ability to raise capital.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-24
Item 3.01
Nasdaq notified Fathom Holdings on August 21, 2026, that the company's stock bid price had closed below the $1.00 minimum for 30 consecutive business days, triggering a notice of non-compliance with Nasdaq Listing Rule 5550(a)(2). The company has until February 17, 2027, to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued public listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-21
Item 3.01
The Company received a deficiency letter from Nasdaq on August 19, 2026, notifying it of non-compliance with Nasdaq Listing Rule 5450(a)(2) due to failure to maintain the minimum 400 shareholders required for continued listing. The Company has 45 days to submit a compliance plan and up to 180 days to regain compliance, with delisting risk if it fails to do so. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-20
Item 3.01
Following completion of the merger, Liberty Broadband notified Nasdaq of the delisting of its shares (LBRDA, LBRDK, LBRDP) effective following the merger's effective time, with plans to file Form 25 for removal from listing and Form 15 for termination of registration.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-20
T3 Defense received a Nasdaq Notification Letter on August 20, 2026 stating it failed to meet the minimum stockholders' equity requirement of $10,000,000 under Nasdaq Listing Rule 5450(b)(1)(A), with stockholders' equity declining to negative $19,659,000 as of June 30, 2026. The company has 45 days to submit a compliance plan or face potential delisting, making this a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-20
Item 3.01
Webster Financial requested suspension of trading and withdrawal of Webster Common Stock and Webster Preferred Stock from NYSE listing effective August 20, 2026, in connection with the closing of the merger transactions. The successor entity intends to file Form 15 to deregister the securities and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-20
Item 3.01
Rising Dragon Acquisition Corp. received a written notice from Nasdaq on August 19, 2026, that its Market Value of Listed Securities fell below the $35 million minimum required for continued listing on the Nasdaq Capital Market. The company has 180 calendar days (until February 16, 2027) to regain compliance; failure to do so will result in delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued exchange listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-20
EX-99.1
The press release discloses receipt of a Nasdaq Listing Qualifications Staff Determination Letter on August 18, 2026, notifying the Company that it has failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The Company has been granted a 180-calendar-day compliance period (until February 16, 2027) to regain compliance, with potential for an additional 180-day period if certain conditions are met. This is a material delisting risk disclosure under Item 3.01 equivalent, as it directly threatens the Company's continued listing on Nasdaq and would significantly affect investor assessment of the registrant's status and trading liquidity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-20
Item 3.01
Ocean Power Technologies received a notice from NYSE Regulation on August 14, 2026, stating non-compliance with continued listing standards under Section 1007 of the NYSE American Company Guide due to failure to timely file its Form 10-K by the extended due date of August 13, 2026. Although the Company cured the deficiency by filing the Form 10-K on August 19, 2026, the Item 3.01 disclosure itself documents the delisting notice and the cure period framework, which is the hallmark of delisting_risk classification. The materiality is clear: a delisting notice directly threatens the registrant's continued listing status and would significantly affect investor assessment.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-20
The filing discloses that RenovoRx received a Nasdaq non-compliance notice on December 31, 2025 for failing the Minimum Bid Price Requirement (closing bid below $1.00 for 30 consecutive business days), and subsequently regained compliance on August 20, 2026 when the stock closed at $1.00 or greater for ten consecutive business days. This is a delisting-risk event—the company was at risk of delisting and has now cured the deficiency. The materiality is clear: listing compliance directly affects investor access and trading liquidity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-20
Item 3.01
BullFrog AI received notice from Nasdaq on August 18, 2026, that while it has not regained compliance with the Minimum Bid Price Requirement (closing bid price below $1.00 per share), it has been granted a second 180-calendar-day compliance period until February 8, 2027. The filing explicitly states that if the Company does not regain compliance by that date, "the Company's listed securities will be subject to delisting." This is a direct delisting risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-20
EX-99.1
SU Group announced it has "regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)" and is "in compliance with the Nasdaq Capital Market's listing requirements." This disclosure directly addresses a delisting risk — the company was previously non-compliant with Nasdaq's minimum bid price rule and has now resolved that deficiency. The announcement confirms the Class A Ordinary Shares will "continue to be listed and traded on The Nasdaq Stock Market," resolving an imminent delisting threat.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-19
Item 8.01
SmartKem announced a 1-for-50 reverse stock split explicitly "intended to increase the per share trading price of Smartkem's common stock to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market." This disclosure directly addresses delisting risk and the company's remedial action to maintain compliance with Nasdaq listing standards, making it a material event that would affect investor assessment of the registrant's exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-19
Item 3.01
Mereo received a second notice from Nasdaq on August 18, 2026, indicating failure to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). While the company has been granted an additional 180-day compliance period until February 16, 2027, the disclosure explicitly states that failure to regain compliance will result in delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the company's continued listing status and investor confidence.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 85%
filed 2026-08-19
The Company announced an ADS ratio change (1-for-10 reverse split) effective August 21, 2026, explicitly to "regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per ADS for continued listing." The disclosure acknowledges that the Company's stock price had fallen below the minimum bid price threshold and that there is no assurance the reverse split will restore compliance. This is a material delisting-risk disclosure under Item 3.01 equivalent, as it signals the registrant's failure to satisfy a continued listing rule and the remedial action taken.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-19
Item 3.01
OSR Health received a Staff Delisting Determination from Nasdaq on August 19, 2026, notifying the company that its common stock and warrants will be delisted from the Nasdaq Capital Market due to failure to maintain the minimum $1.00 closing bid price required by Nasdaq Listing Rule 5550(a)(2). Trading suspension is scheduled for August 26, 2026, with formal delisting to follow unless the company successfully appeals to the Nasdaq Hearings Panel.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-08-19
Item 3.01
Trio-Tech International's common stock listing is being transferred from NYSE American (NYSE MKT) to Nasdaq Global Market, effective September 16, 2026, with trading on NYSE American ceasing on September 15, 2026.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-19
EX-99.1
K Wave Media announced that it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2), confirming that the closing bid price met or exceeded $1.00 per share for 10 consecutive business days. This disclosure directly addresses a delisting risk — the company was previously non-compliant with a continued listing standard and has now cured that deficiency. The announcement explicitly states "the matter is now closed," confirming resolution of the compliance violation.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-18
Item 3.01
Skye Bioscience received a written notice from Nasdaq on August 18, 2026, stating that the company failed to comply with Nasdaq Capital Market Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000. The company's stockholders' equity was ($497,307)—negative—as of June 30, 2026. Although the notice has no immediate effect on listing, the company has 45 calendar days to submit a compliance plan and up to 180 days to regain compliance, with explicit acknowledgment that "there can be no assurance that the Company will be able to regain compliance." This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-17
Item 3.01
Talkspace notified NASDAQ on August 17, 2026, requesting suspension of trading and filing of Form 25 to delist and deregister its common stock under Section 12(b) of the Exchange Act, effective 10 days after Form 25 filing, and intends to file Form 15 to terminate registration under Section 12(g).
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-17
Item 3.01
Following completion of the merger, AvalonBay Common Stock was delisted from the NYSE effective August 17, 2026, with the NYSE filing Form 25 to remove the stock from trading and triggering deregistration under Section 12(b) of the Exchange Act. The successor entity intends to file Form 15 to suspend reporting obligations.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-17
The 6-K discloses that MDJM LTD's Class A ordinary shares have been delisted from Nasdaq following a final decision by the Nasdaq Listing and Hearing Review Council on July 28, 2026, affirmed by the Nasdaq Board on August 12, 2026. The Company's shares are now quoted only on the OTCQB Venture Market under ticker "UOKAF." This is a material delisting event that materially affects the registrant's market access and investor base.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-17
Item 8.01
T3 Defense received notice from Nasdaq on August 17, 2026 that it regained compliance with the minimum bid price requirement of $1.00 per share under Listing Rule 5450(a)(1). This disclosure directly addresses a delisting risk: the company had previously failed to maintain the minimum bid price (as disclosed in a May 8, 2026 8-K) and now reports restoration of compliance. The event is material because it resolves a significant threat to the company's continued listing on Nasdaq.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 75%
filed 2026-08-17
The NYSE has imposed a trading halt on the Company's ADSs following disclosure of a delayed IPO closing. The Company's ADSs began trading on August 12, 2026 on a when-issued basis but the offering has not closed as of the filing date (August 17, 2026) due to unresolved regulatory complaints concerning the controlling shareholders' compliance and restructuring transactions. While the filing does not explicitly state delisting, a trading halt combined with a failed IPO closing and ongoing regulatory issues creates material delisting risk under Item 3.01 standards.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-17
EX-99.1
The announcement discloses a 1-for-40 reverse stock split undertaken specifically "to satisfy the minimum bid price requirement for maintaining listing on Nasdaq." This is a direct response to delisting risk — the company explicitly states the reverse split's purpose is to "increase the market price of the Company's common stock and allow it to satisfy the minimum bid price requirement for maintaining listing on Nasdaq," indicating the company was at risk of failing Nasdaq's continued listing standards.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-17
Akanda Corp. received a Nasdaq deficiency letter on June 16, 2026, for failing to maintain the minimum $2.5 million stockholders' equity required under Nasdaq Listing Rule 5550(b)(1). Although Nasdaq granted an extension through December 13, 2026, the filing explicitly states "The Company's failure to meet these requirements could result in the Company's securities being delisted from Nasdaq." This is a clear delisting risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-17
Item 3.01
Helix Acquisition Corp. III received a written notice from Nasdaq on August 14, 2026, indicating non-compliance with Listing Rule 5452(a)(2)(A) regarding the Minimum Total Holders Requirement (at least 300 total holders). Although the notice is characterized as a deficiency notification rather than imminent delisting, the Company has 45 calendar days to submit a compliance plan or face potential delisting proceedings. This is a classic delisting-risk disclosure under Item 3.01, material to investors as it threatens continued listing on Nasdaq Global Market.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-17
Fast Track Group received a Staff Determination letter from Nasdaq on August 11, 2026, notifying the Company of its determination to delist the Company's securities from The Nasdaq Capital Market due to failure to maintain a minimum bid price of $1.00 or higher under Listing Rule 5550(a)(2). Trading suspension is scheduled for August 18, 2026, with the Company intending to appeal and request a hearing before a Hearings Panel. This is a clear delisting risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-17
Item 8.01
The filing discloses that Lexaria has cured a Nasdaq bid price deficiency and regained compliance with Listing Rule 5550(a)(2), resulting in cancellation of a previously requested delisting hearing. While the news is positive (cure achieved), the disclosure itself centers on a delisting risk event—the company was previously non-compliant with continued listing standards and faced potential delisting. This is material to investors as it directly affects the registrant's exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-17
Item 3.01
Cloudastructure received a Nasdaq notification on February 17, 2026 for failure to maintain the $1.00 minimum bid price requirement, with a 180-day compliance period ending August 17, 2026; the company regained compliance on August 14, 2026 when its stock maintained the minimum bid price for 10 consecutive business days.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-17
EX-99.1
The exhibit discloses that NYSE American accepted Mynd's compliance plan following a June 2, 2026 notice of non-compliance with continued listing standards (Sections 1003(a)(i) and (ii)) due to stockholders' deficit as of December 31, 2025. The company has been granted an extension through December 2, 2027 to regain compliance. This is a material delisting-risk disclosure: the company faced a listing threat, submitted a remediation plan, and received conditional approval to remain listed pending achievement of specified milestones. The language "maintain its NYSE American listing while executing initiatives" and "remain listed on NYSE American during this period" confirms the conditional nature of continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-17
Item 3.01
Nexalin received a Nasdaq Staff letter on August 14, 2026, notifying the company that it fails to meet the minimum stockholders' equity requirement of $2,500,000 (reporting only $1,519,423 as of June 30, 2026) under Nasdaq Listing Rule 5550(b)(1). This stockholders' equity deficiency, combined with a previously disclosed bid price deficiency, creates dual grounds for delisting. The company faces a hearing on September 1, 2026, with no assurance of success, and explicit acknowledgment that delisting would have material adverse effects on liquidity, stock price, and capital-raising ability.
View raw filing on EDGAR →